Despite analysts downgrading revenue estimates and increasing loss per share forecasts for Akeso, the consensus price target remains steady. However, Akeso's revenues are expected to underperform the wider industry.
Akeso's weaker revenue outlook doesn't impact its P/S ratio as much as expected, posing a risk to investors. The share price may fall if low revenue growth affects sentiment. Investors should consider this risk before investing.
$恒生指数(800000.HK)$plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion. Pharmaceuticals were sold off.$荣昌生物(09995.HK)$once collapsed 27.5% to $22.8; last at $24.9, down 21%. $三叶草生物-B(02197.HK)$nosedived 9.6% to $0.47, hitting record low.$维亚生物(01873.HK)$...
Akeso's low P/S ratio indicates shareholder discomfort over its weak future revenue forecast. The market's gloomy sentiment about the company's growth prospects affects the low P/S ratio.
Akeso's strong net cash position and high liquidity suggest a low risk in its debt usage. The large conversion rate of EBIT to free cash flow also signals a positive financial health and potential profitability.
$康方生物(09926.HK)$Excellent clinical data, focus on product launch and data disclosure Phase II clinical trial of AK112 combined with paclitaxel and chemotherapy in advanced non-small cell lung cancer Objective sustained release rate (ORR) 53.8%, disease control rate (DCR) 100%, grade 3 or above treatment The incidence of related adverse events was 13.5%. In combination with the PARP inhibitor olaparil for ovarian cancer Phase Ib/II clinical, ORR/DCR 40.0%/86.7%. We expect it to be around 2024 on the market.
康方生物股票讨论区
Pharmaceuticals were sold off. $荣昌生物(09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$三叶草生物-B(02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $维亚生物(01873.HK)$ ...
Phase II clinical trial of AK112 combined with paclitaxel and chemotherapy in advanced non-small cell lung cancer
Objective sustained release rate (ORR) 53.8%, disease control rate (DCR) 100%, grade 3 or above treatment
The incidence of related adverse events was 13.5%. In combination with the PARP inhibitor olaparil for ovarian cancer
Phase Ib/II clinical, ORR/DCR 40.0%/86.7%. We expect it to be around 2024 on the market.
暂无评论